96,207 results on '"Ovarian Neoplasms"'
Search Results
52. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
53. Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
54. Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab and Pegylated Liposomal Doxorubicin as Treatment for Ovarian Cancer. (PROTA)
55. Efficacy and Safety of SBRT in Oligo-metastatic/Persistent/Recurrent Ovarian Cancer (MITO-RT3/RAD)
56. Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer
57. Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
58. Assessment of Safety of Olaparib in Chinese Patients With Ovarian Cancer in the Real-World Setting
59. Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA)
60. A Non-interventional Prospective Study of 1-st Line Treatment Approaches in OVArian Cancer Patients With HRD+ Status in Russian Federation (OVARD)
61. With Love, Grandma ("Con Cariño, Abuelita") Pilot Study
62. Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
63. Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
64. Evaluation of Amino Acid Metabolism Changes in Ovarian Cancer (AMINOCANCER)
65. Non-interventional Study to Collect Real-world Clinical and Patient-reported Outcomes in Ovarian Cancer (SCOUT-1)
66. Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer
67. HRD Tests for Ovarian cancER (HERO)
68. Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT (PembroSCCOHT)
69. Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
70. A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer
71. LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
72. Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
73. Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer
74. Study Evaluating Safety, Tolerability, and Metabolism of Niraparib
75. Abdominopelvic Cancer Prehabilitation
76. Measuring Oncological Value of Exercise and Statin (MOVES)
77. SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
78. Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer (ECHO)
79. ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer
80. Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
81. Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy (L-MOCA)
82. Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
83. Prognostic and Predictive Biomarkers in Ovarian Cancers (OvBIOMark)
84. Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT
85. A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
86. A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (BOUQUET)
87. A Study of SGN-B6A in Advanced Solid Tumors
88. NeoVax With Nivolumab in Patients With Ovarian Cancer
89. A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
90. 4FMFES-PET Imaging of Endometrial and Ovarian Cancers
91. IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOC (IMPACT)
92. Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer
93. A Trial of Vigil for Participants With Ovarian Cancer (VITAL)
94. Prophylactic Salpingectomy With Delayed Oophorectomy
95. Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer
96. Improved Diagnosis of Ovarian Cancer
97. Improved Diagnosis of Ovarian Cancer by Use of Circulating Tumor DNA as a Biomarker
98. Trial on Radical Upfront Surgery in Advanced Ovarian Cancer (TRUST)
99. Timing of Surgery After Neoadjuvant Chemotherapy for Advanced Ovarian Cancer
100. Predicting Outcome of Cytoreduction in Advanced Ovarian Cancer, Using a Machine Learning Algorithm and Patterns of Disease Distribution at Laparoscopy (PREDAtOOR) (PREDAtOOR)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.